Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.

ABSTRACT:

Purpose

Palliative treatment options for HR + HER2- advanced breast cancer (ABC) patients have increased, but data is lacking about the optimal treatment sequence. We used real-world data from a comprehensive cancer center to describe applied treatment sequences and we determined treatment-related and survival outcomes.

Methods

Patients aged 18 years and older with HR + HER2- ABC treated with systemic treatment were included in this historic cohort study. Sequential treatment schedules, time to treatment discontinuation, time to chemotherapy, and overall survival (OS) were determined, stratified by first-line treatment.

Results

202 patients were included. They received a total of 650 treatment lines (median 3; range: 1-11). 91 (45%), 25 (12%), 24 (12%), 28 (14%), 22 (

SUBMITTER: Almekinders CAM 

PROVIDER: S-EPMC11787233 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature